重组人血管内皮抑制素注射液联合同步放化疗对晚期非小细胞肺癌的临床疗效及预后的影响因素分析

Analysis of the clinical efficacy and prognostic factors of recombinant human endostatin injection combined with concurrent chemoradiotherapy in the treatment of advanced non-small cell lung cancer

目的分析重组人血管内皮抑制素注射液联合同步放化疗对晚期非小细胞肺癌(NSCLC)的临床疗效及预后的影响因素。方法选取2018年1月至2019年1月上饶市第五人民医院收治的60例晚期NSCLC患者作为研究对象,随机分为对照组与观察组,各30例。对照组采用同步放化疗治疗,观察组采用重组人血管内皮抑制素注射液联合同步放化疗治疗,比较两组临床疗效、不良反应发生率,统计2年后的生存情况,采用单因素及多因素分析分析影响患者生存情况的危险因素。结果观察组治疗总有效率为80.00%,高于对照组的53.33%,差异有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义;两组1年生存率、2年生存率比较差异无统计学意义;单因素分析结果显示,生存与死亡患者肿瘤最大直径、临床分期、吸烟、卡氏功能状态评分(KPS)比较差异有统计学意义(P<0.05);多因素分析结果显示,肿瘤最大直径>6 cm、临床分期Ⅲb期、吸烟、KPS评分<70分是影响晚期NSCLC患者预后的独立危险因素(P<0.05)。结论重组人血管内皮抑制素注射液联合同步放化疗治疗晚期NSCLC的疗效显著,不会增加不良反应,患者预后情况与肿瘤最大直径、临床分期、吸烟、KPS评分显著相关。

Objective To analyze the clinical efficacy and prognostic factors of recombinant human endostatin injection combined with concurrent chemoradiotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 60 patients with advanced NSCLC admitted to Shangrao Fifth People's Hospital from January 2018 to January 2019 were randomly divided into the control group and the observation group,with 30 cases in each group.The control group was treated with concurrent chemoradiotherapy,and the observation group was treated with recombinant human endostatin injection combined with concurrent chemoradiotherapy.The clinical efficacy and incidence of adverse reactions were compared between the two groups,the survival after 2 years was counted.Univariate and multivariate analysis were used to analyze the risk factors affecting the survival of patients.Results The total effective rate of treatment in the observation group was 80.00%,which was higher than 53.33%in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups;there was no significant difference in 1-year survival rate and 2-year survival rate between the two groups.Univariate analysis showed that there were significant differences in the maximum diameter of tumor,clinical stage,smoking and Karnofsky performance status(KPS)score between the survival and the death patients(P<0.05).Multivariate analysis showed that the maximum tumor diameter>6 cm,clinical stageⅢb,smoking,and KPS score<70 were independent risk factors affecting the prognosis of patients with advanced NSCLC(P<0.05).Conclusion Recombinant human endostatin injection combined with concurrent chemoradiotherapy is effective in the treatment of advanced NSCLC,without increasing adverse reactions,the prognosis of patients is significantly related to the maximum diameter of tumor,clinical stage,smoking and KPS score.